Assignee
DECIPHER BIOSCIENCES INC
US·7 granted patents·7 pending applications·31 citations·filing 2012–2022
Top patents by PatentIndex Score
14 records- 0191US10865452B2Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancerDECIPHER BIOSCIENCES INC·Filed 2016·Granted Dec 15, 2020·7 cites·14 claims
- 0287US10513737B2Cancer diagnostics using non-coding transcriptsDECIPHER BIOSCIENCES INC·Filed 2012·Granted Dec 24, 2019·9 cites·7 claims
- 0384US11208697B2Molecular subtyping, prognosis, and treatment of bladder cancerDECIPHER BIOSCIENCES INC·Filed 2018·Granted Dec 28, 2021·5 cites·11 claims
- 0484US11078542B2Genetic signatures to predict prostate cancer metastasis and identify tumor aggressivenessDECIPHER BIOSCIENCES INC·Filed 2018·Granted Aug 3, 2021·3 cites·3 claims
- 0582US11414708B2Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapyDECIPHER BIOSCIENCES INC·Filed 2017·Granted Aug 16, 2022·3 cites·9 claims
- 0667US2022349011A1Cancer diagnostics using biomarkersDECIPHER BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 0766US11035005B2Cancer diagnostics using biomarkersDECIPHER BIOSCIENCES INC·Filed 2013·Granted Jun 15, 2021·4 cites·14 claims
- 0866US2022177974A1Genetic signatures to predict prostate cancer metastasis and identify tumor aggressivenessDECIPHER BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 0965US2022325352A1Molecular subtyping, prognosis, and treatment of bladder cancerDECIPHER BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 1059US2024002944A1Methods and genomic classifiers for identifying homologous recombination deficiency prostate cancerDECIPHER BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 1157US2024319192A1Use of immune content scores diagnostically to predict responsiveness of prostate cancer patients to immunotherapyDECIPHER BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 1254US2023115828A1Genomic classifiers for prognosing and treating clinically aggressive luminal bladder cancerDECIPHER BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 1351US2022213557A1Non-coding rna for subtyping of bladder cancerDECIPHER BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 1445US12497660B2Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapyDECIPHER BIOSCIENCES INC·Filed 2018·Granted Dec 16, 2025·0 cites·19 claims
Join the waitlist — get patent alerts
Get an alert when DECIPHER BIOSCIENCES INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →